Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker

Area of Science:

• Epigenetics
• Medicinal Chemistry
• Cancer Biology

Background:

• Epigenetic mechanisms, including DNA methylation and histone modifications, play a crucial role in cancer development.
• Histone acetylation, regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), is often dysregulated in tumors.
• Histone deacetylase inhibitors (HDACIs) are emerging as potential chemotherapeutic agents due to HDACs' aberrant function in cancer.

Purpose of the Study:

• To synthesize and evaluate novel hydroxamic acid-based HDAC inhibitors.
• To investigate the inhibitory potential and antiproliferative activity of these compounds against cancer cell lines.

Main Methods:

• Synthesis of a series of hydroxamic acid-based HDACIs featuring pyrazole and cinnamoyl moieties.
• Molecular docking studies to assess binding interactions.
• Biological evaluation of inhibitory activity against HDACs and antiproliferative effects on neuroblastoma SH-SY5Y cells.

Main Results:

• Several synthesized compounds demonstrated inhibitory activity against HDACs.
• Some compounds exhibited significant antiproliferative effects on the neuroblastoma SH-SY5Y cell line at micromolar concentrations.
• Docking studies provided insights into the binding modes of the inhibitors.

Conclusions:

• The developed hydroxamic acid-based compounds represent a promising class of potential HDAC inhibitors.
• These findings support the therapeutic potential of targeting epigenetic dysregulation in neuroblastoma and other cancers.